-
Presentation
Presentation
The UC is focused on the role of genetic changes in drug response in terms of efficacy and safety. The topics covered in this UC are current and extremely important for the formation of the pharmacist, preparing him with knowledge in an area that is gaining increasing importance in the different drug areas (e.g. Clinical Trials or Hospital Pharmacy). Increasingly, through pharmacogenomics it is possible to have an individualized therapy, guaranteed maximum effectiveness and preventing several safety problems.
-
Class from course
Class from course
-
Degree | Semesters | ECTS
Degree | Semesters | ECTS
Bachelor; Master Degree | Trimestral | 4
-
Year | Nature | Language
Year | Nature | Language
4 | Mandatory | Português
-
Code
Code
ULHT477-8498
-
Prerequisites and corequisites
Prerequisites and corequisites
Not applicable
-
Professional Internship
Professional Internship
Não
-
Syllabus
Syllabus
Pharmacogenetics and pharmacogenomics Definition and general concepts Positive outcomes of pharmacogenomics The relationship of pharmacogenomics with pharmacokinetics and pharmacodynamics Main goal of pharmacogenomics: gene analysis, genome-wide association studies e human genome project Methodologies Methods applied in clinical practice DNA analysis: PCR e DNA sequencing Personalized medicine Background, concepts, main goals and clinical applications of personalized medicine Advantages and clinical application of pharmacogenomics: Cardiovascular diseases Oncological diseases Neurological diseases Pharmacogenomics: ethical, legal and social concepts
-
Objectives
Objectives
Pharmacogenomics studies how genetic differences between individuals can affect responses to various drugs. Following medicine skills acquired by the student and his action in different pathologies, pharmacogenomics enables him to acquire knowledge about the influence of genetic alterations on the therapeutic effect and adverse reactions of the drugs, from a perspective of individualized therapy. Thus, with this CU it is intended that the student can: - Understand how genetic changes influence the pharmacokinetics and pharmacodynamics of drugs; - Know different techniques used in clinical practice that allow to detect the genetic alterations; - Recognize the importance of Pharmacogenomics in personalized medicine to increase the therapeutic effect and reduce the toxicity of the drugs; - Know the clinical applications of Pharmacogenomics in different pathologies (ex: cardiovascular, oncological and neurological).
-
Teaching methodologies and assessment
Teaching methodologies and assessment
In the Pharmacogenomics CU, innovative learning tools are used, such as websites and online databases with genetic variations and polymorphisms and their clinical impact. These tools will make it easier to identify the impact of genetic alterations on the efficacy and safety of drugs. These tools will be useful for a better understanding of the syllabus, with images, diagrams and videos, which will increase students' interest and learning. In addition, the students will have fieldwork, which will consist of a class open to the entire community, with the presentation of group work, with the students involved from the creation of flyers and posters, to online dissemination to the entire community, not just academics. The aim is to stimulate learning and give students an active role in demonstrating the potential of pharmacogenomics in the pharmaceutical profession to students, health professionals and others.
-
References
References
Lam, Y. W. F., & Scott, S. R. (Eds.). (2018). Pharmacogenomics: challenges and opportunities in therapeutic implementation. Elsevier - Academic Press. Feng, X., & Xie, H. G. (Eds.). (2016). Applying pharmacogenomics in therapeutics. CRC Press. Padmanabhan, S. (Ed.). (2014). Handbook of pharmacogenomics and stratified medicine. Elsevier - Academic Press. Liu, Y. (Ed.). (2014). Omics in Clinical Practice: Genomics, Pharmacogenomics, Proteomics, and Transcriptomics in Clinical Research. CRC Press.
-
Office Hours
Office Hours
-
Mobility
Mobility
No
